Acellular Dermal Matrices Market Size to Exceed USD 24.58 Bn by 2032

The Acellular Dermal Matrices Market, estimated at USD 11.05 Bn in 2025, is expected to exhibit a CAGR of 12.1% and reach USD 24.58 Bn by 2032.

The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.

Various research institutes and biotechnology companies are engaged in conducting research and development activities for acellular dermal matrix, and this is expected to drive the global acellular dermal matrices market growth. For instance, in October 2025, The Plastic Surgery Foundation (PSF), an organization that supports the research and international activities of the members of the American Society of Plastic Surgeons (ASPS), received U.S. Food and Drug Administration (FDA) approval for its Investigational Device Exemption (IDE) application, and will proceed as the sponsor of a prospective, multicenter observational trial studying the impact of acellular dermal matrix (ADM) and surgical mesh in implant-based breast reconstruction.

Global Acellular Dermal Matrices Market – Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2025, as "coronavirus disease 2025" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems regarding transportation of raw materials and manufacturing supplies from one place to another.

Moreover, COVID-19 had negative impact on global acellular dermal matrices market as numerous elective procedures, particularly reconstructive and aesthetic treatments that frequently involve ADM, were postponed or cancelled during the pandemic's peak. This led to reduced demand for these products. For instance, in May 2025, according to Journal of Plastic, Reconstructive & Aesthetic Surgery Open Journal, in 2025 about 28 million elective surgeries were postponed or canceled worldwide. Internationally, there was a 10.9% reduction in aesthetic surgical operations from 2025 to 2025, owing to many cosmetic and reconstructive surgery procedures being deemed elective.

Global Acellular Dermal Matrices Market: Key Developments

In March 2025, Bimini Health Tech, a medical equipment provider, announced the exclusive acquisition of Acellular Dermal Matrix (ADM) technology from Ideal Implant, Inc., a provider of artificial breast implants for use in cosmetic and reconstructive surgery. The ADM technique employs a patented manufacturing method that eliminates donor DNA without affecting the required biomechanical structure or biochemical qualities, keeping crucial elements of the native dermis intact for integration and neovascularization to suit its intended usage.

Browse 35 Market Data Tables and 31 Figures spread through 180 Pages and in-depth TOC on “Global Acellular Dermal Matrices Market, By Origin (Human Dermis, Porcine Dermis, and Bovine Dermis), By Application (Acute Wounds (Burns, Trauma, Cancers, and Infections), Chronic Wounds (Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcer, and Others), and Reconstruction Procedures (Abdominal Wall Procedures, Breast Procedures, Orthopedic Procedures, and Others), By Place of Setting (Hospitals (in-patient, out-patient), Ambulatory Surgical Centers, and Office Based), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/acellular-dermal-matrices-market-4362

Key Takeaways of the Global Acellular Dermal Matrices Market:

Global acellular dermal matrices market is expected to exhibit a CAGR of 12.1% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global acellular dermal matrices market.
Among application, the reconstruction procedures segment is expected to hold a dominant position in the global acellular dermal matrices (ADM) market over the forecast period due to increasing agreements to distribute ADM for reconstruction procedures. For instance, in March 2025, Aziyo Biologics, Inc., a company that develops and commercializes biologic products, and Sientra, Inc., a medical aesthetics firm that specializesin plastic surgery, announced that both companies had signed an agreement to increase the distribution of Aziyo's SimpliDerm product line. Aziyo will provide Sientra certain non-exclusive rights to advertise, sell, and distribute SimpliDerm, a pre-hydrated human acellular dermal matrix (hADM) in the U.S. under the terms of the agreement.
Among region, North America is expected to be the dominant region in the global acellular dermal matrices market owing to increasing product approvals by the regulatory authorities in the region. For instance, in January 2025, MedSkin Solutions, a global provider of private label premium skin care products, announced that the MatriDerm product portfolio had received 510(k) approval from the U.S. Food and Drug Administration (U.S.FDA). MatriDerm is a single-use 3D acellular wound dressing made of cow collagen fibres and bovine elastin dermal matrix. It is intended to treat full thickness and partial thickness wounds.
Major players operating in the global acellular dermal matrices market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, CG bio Inc., and Marine Polymer Technologies, Inc.